Mohammed Ali, MD
Gastroenterology · Chevy Chase, MDNPI 1962476143
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,693 of the $48,616 with a category attached, or 83.7%. 27 manufacturers reported payments, led by Meridian Bioscience Inc. at 44.9% of the total. Reporting peaked in 2021 at $20,579 and has fallen 97.8% since, to $446 in 2025. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $214.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Meridian Bioscience Inc.$22K
- Medtronic$22K
- AbbVie$2K
- Roche Diagnostics Corporation$901
- Bristol Myers Squibb$519
- Johnson & Johnson$425
- plus $2K from 21 others
What the payments were for
- Royalty or licence$2250%
- Consulting fees$40,69384%
- Travel & lodging$2,6655%
- Food & beverage$4,79310%
- Education$2410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Meridian Bioscience Inc. | 15 | $21,851 |
| Medtronic | 24 | $21,542 |
| AbbVie(2 entities) | 69 | $1,575 |
| Roche Diagnostics Corporation | 5 | $901 |
| Bristol Myers Squibb | 39 | $519 |
| Johnson & Johnson | 10 | $425 |
| Pfizer | 21 | $345 |
| E.r. Squibb & Sons, L.L.C. | 2 | $253 |
| Sanofi | 4 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $199 |
| Conmed Corporation | 1 | $151 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $142 |
| Boston Scientific | 1 | $115 |
| Ardelyx, Inc. | 1 | $60 |
| Celltrion USA Inc. | 3 | $60 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Braintree Laboratories, Inc. | 3 | $41 |
| Ferring Pharmaceuticals Inc. | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Endogastric Solutions, Inc | 1 | $15 |
| Merck | 1 | $11 |
| QOL Medical, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PillCam$1,622
- iScan Coreo$609
- Rinvoq$237
- VIRTUOSO System for IHC$213
- AIRSEAL$151
- STELARA$143
- DUPIXENT$135
- GI Genius$131
- ZEPOSIA$118
- GENERAL BIOPSY$115
- Entyvio$101
How this compares
$48,616 in reported general payments places this provider in the 90th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 25 | $20,354 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 180 | $10,838 |
| Mesalamine | 17 | $9,667 |
| MotegrityPrucalopride Succinate | 12 | $9,212 |
| Dexlansoprazole DrDexlansoprazole | 16 | $5,074 |
| Mesalamine ErMesalamine | 11 | $3,822 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 18 | $2,964 |
| Omeprazole | 155 | $2,565 |
| Esomeprazole Magnesium | 12 | $1,966 |
| Pantoprazole Sodium | 72 | $1,694 |
| Budesonide EcBudesonide | 13 | $1,516 |
| Famotidine | 50 | $632 |
| Ondansetron OdtOndansetron | 13 | $237 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,575 | $20,35425 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $199 | $9,21212 claims |
| Braintree Laboratories, Inc.Sutab | $41 | $2,96418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Chevy Chase
- Zachary BormanChevy Chase$520K
- Erica CohenChevy Chase$385K
- Louis KormanChevy Chase$19K
- Apurva ModiRockville$1.1M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Mouen KhashabBaltimore$440K
- Natarajan RavendhranCatonsville$367K
- Raymond CrossBaltimore$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.